Evaluation of Phenobarbital Serum Levels on Clinical Outcomes for the Treatment of Severe Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit
Journal of Pharmacy Practice · 13.05.2026
DOI: 10.1177/08971900261450711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 13.05.2026. Verfasst von Moqadam S Rhamatzada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA. Die Arbeit nennt 16 Literaturangaben.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Optimal phenobarbital serum levels for treating severe alcohol withdrawal syndrome (AWS) remain unclear.
Objective
This study evaluated whether phenobarbital serum levels are associated with symptom control in patients with severe AWS admitted to a medical intensive care unit (MICU).
Methods
We conducted a single-center, retrospective analysis of adult MICU patients treated with phenobarbital for severe AWS between January 2011 and December 2022. Patients were categorized into two cohorts based on symptom control status: (1) symptom controlled and (2) non-symptom controlled. The primary objective was to assess the relationship between phenobarbital serum levels and symptom control. Secondary objectives evaluated dosing regimens and safety outcomes.
Results
Of 114 patients (63 symptom controlled, 51 non-symptom controlled), no significant association was found between phenobarbital levels (32.2 ± 19.9 vs 36.9 ± 16.0 mcg/mL) (mean, SD) and symptom control ( P = 0.08). Phenobarbital dosing regimen, loading dose (LD) ± as needed (PRN) doses (n = 49) vs PRN only (n = 65), was not significantly associated with MICU LOS ( P = 0.09). However, treatment duration was shorter in the PRN only group (median 54 vs 97 hours; P = 0.016). Endotracheal intubation and vasopressor use were more common in non-symptom controlled patients. No mortality occurred in either group.
Conclusion
No significant evidence was found to suggest that phenobarbital serum levels were associated with symptom control in patients admitted to a MICU for severe AWS as defined in this study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Services, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Northshore University Medical Center, Northwell Health, Manhasset, NY, USA.
- Medical Intensive Care Unit, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA.
- SVP, Critical Care Services, Medical Director of the Acute Lung Injury/VV ECMO Program, Northwell Health, New Hyde Park, NY, USA.
- Office of Academic Affairs, Northwell Health, New Hyde Park, NY, USA.
ORCID-Profile: Keith P Falsetta
Zitieren
APA
Rhamatzada, M. S., Schweiger, K. A., Mayo, P. H., Hasan, Z. M., Narasimhan, M., Fishbein, J. S., & Falsetta, K. P. (2026). Evaluation of Phenobarbital Serum Levels on Clinical Outcomes for the Treatment of Severe Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900261450711
Vancouver
Rhamatzada MS, Schweiger KA, Mayo PH, Hasan ZM, Narasimhan M, Fishbein JS, et al. Evaluation of Phenobarbital Serum Levels on Clinical Outcomes for the Treatment of Severe Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit. Journal of Pharmacy Practice. 2026. doi:10.1177/08971900261450711
BibTeX
@article{Rhamatzada2026,
author = {Rhamatzada, Moqadam S and Schweiger, Krislyn A and Mayo, Paul H and Hasan, Zubair M and Narasimhan, Mangala and Fishbein, Joanna S and Falsetta, Keith P},
title = {Evaluation of Phenobarbital Serum Levels on Clinical Outcomes for the Treatment of Severe Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit},
journal = {Journal of Pharmacy Practice},
year = {2026},
doi = {10.1177/08971900261450711}
}
EUVIMED